Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome.
[8] By attaching to the C5 protein, the medicine blocks its effect and thereby reduces the destruction of red blood cells.
[8] In the United States, ravulizumab is indicated for the treatment of adults and children one month of age and older with paroxysmal nocturnal hemoglobinuria and for the treatment of adults and children one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
[7][9] In the European Union, ravulizumab is indicated in the treatment of adults with paroxysmal nocturnal haemoglobinuria: The most common side effects are upper respiratory tract infection (nose and throat infection), nasopharyngitis (inflammation of the nose and throat) and headache.
[8][7] Ravulizumab was developed by Alexion Pharmaceuticals, Inc.[10] It was engineered from eculizumab to have a longer-lasting effect.